Free Trial
NASDAQ:DAWN

Day One Biopharmaceuticals Q1 2024 Earnings Report

Day One Biopharmaceuticals logo
$6.27 0.00 (0.00%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$6.30 +0.03 (+0.46%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.67
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Day One Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Day One Biopharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, July 8, 2025

Day One Biopharmaceuticals Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat